1921
Volume 100, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Local therapies have been proposed as safe and effective alternatives to systemic drugs in cutaneous leishmaniasis (CL), especially among less severe cases. However, they are not widely available and used in endemic places, including Colombia, which has a high burden of disease. Further complicating the uptake of local therapies is that different treatment guidelines have been established by the World Health Organization (WHO) and Pan American Health Organization (PAHO). Using data from a large referral center in Colombia, we determined the proportion of patients who would be eligible for and potentially benefit from local therapies according to both international guidelines. The sample included 1,891 confirmed cases of CL aged ≥ 12 years, mostly infected with (91%, = 601/660), between 2004 and 2014. Overall, 57% of the sample had one lesion, whereas another 31% had two to three lesions. For 74% of patients, all lesions were in an area other than head or neck. The maximum lesion size was ≤ 3 cm for 58% and < 5 cm for 88% of the sample. Based on our data, up to 56% of patients could have been eligible for local therapies according to the WHO criteria. By contrast, only 23% were eligible according to the more restrictive PAHO criteria. Regardless, these data suggest that a substantial proportion of CL patients in Colombia may benefit from local therapies given their relatively mild presentation of disease and low risk of complications. Individualized risk–benefit assessment and guideline adjustments may increase local therapy eligibility and benefit a large number of patients.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-0643
2019-01-07
2020-01-28
Loading full text...

Full text loading...

/deliver/fulltext/14761645/100/2/tpmd180643.html?itemId=/content/journals/10.4269/ajtmh.18-0643&mimeType=html&fmt=ahah

References

  1. WHO, 2017. Weekly Epidemiological Record, Vol. 92, 38. Available at: http://www.who.int/wer/, 557–572. Accessed February 15, 2018.
  2. Goto H, Lauletta Lindoso JA, , 2012. Cutaneous and mucocutaneous leishmaniasis. Infect Dis Clin North Am 26: 293307. [Google Scholar]
  3. Schwartz E, Hatz C, Blum J, , 2006. New world cutaneous leishmaniasis in travellers. Lancet Infect Dis 6: 342349. [Google Scholar]
  4. Instituto Nacional de Salud–Colombia, 2018. Informe Del Evento Leishmaniasis, Hasta El Periodo Epidemiologico XIII, Colombia, 2017. Bogotá, Colombia: INS. [Google Scholar]
  5. Tiuman TS, Santos AO, Ueda-Nakamura T, Filho BPD, Nakamura CV, , 2011. Recent advances in leishmaniasis treatment. Int J Infect Dis 15: e525e532. [Google Scholar]
  6. Organización Panamericana de la Salud, 2013. Leishmaniasis En Las Américas: Recomendaciones Para El Tratamiento. Washington, DC: PAHO. Available at: http://www.paho.org/hq/index.php?option=com_content&view=category&id=3835&layout=blog&Itemid=4098&lang=es. Accessed September 16, 2013. [Google Scholar]
  7. Rubiano LC, 2012. Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children. J Infect Dis 205: 684692. [Google Scholar]
  8. WHO, 2010. Control of the Leishmaniases: Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases. Geneva, Switzerland: World Health Organization. Available at: http://apps.who.int/iris/bitstream/10665/44412/1/WHO%7B_%7DTRS%7B_%7D949%7B_%7Deng.pdf. Accessed April 10, 2018. [Google Scholar]
  9. Brito NC, Rabello A, Cota GF, , 2017. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: a systematic review. PLoS One 12: e0184777. doi: 10.1371/journal.pone.0184777. [Google Scholar]
  10. Soto J, Paz D, Rivero D, Soto P, Quispe J, Toledo J, Berman J, , 2016. Intralesional pentamidine: a novel therapy for single lesions of Bolivian cutaneous leishmaniasis. Am J Trop Med Hyg 94: 852856. [Google Scholar]
  11. Cardona-Arias JA, Vélez ID, López-Carvajal L, , 2015. Efficacy of thermotherapy to treat cutaneous leishmaniasis: a meta-analysis of controlled clinical trials. PLoS One 10: e0122569. [Google Scholar]
  12. Vasconcellos Ede CFE, 2012. Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006). Am J Trop Med Hyg 87: 257260. [Google Scholar]
  13. Blum J, 2012. Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis. Int Health 4: 153163. [Google Scholar]
  14. Blanco VM, Cossio A, Martinez JD, Saravia NG, , 2013. Clinical and epidemiologic profile of cutaneous leishmaniasis in Colombian children: considerations for local treatment. Am J Trop Med Hyg 89: 359364. [Google Scholar]
  15. Organización Panamericana de la Salud, 2017. Leishmaniasis: Informe Epidemiológico En Las Américas. Washington, DC: PAHO. [Google Scholar]
  16. Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, Carvalho EM, Ephros M, Jeronimo S, Magill A, , 2016. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 63: 15391557. [Google Scholar]
  17. Grimaldi GJ, Mcmahon-Pratt D, , 1996. Monoclonal antibodies for the identification of New World Leishmania species. Mem Inst Oswaldo Cruz 91: 3742. [Google Scholar]
  18. Saravia NG, Segura I, Holguin AF, Santrich C, Valderrama L, Ocampo C, , 1998. Epidemiologic, genetic, and clinical associations among phenotypically distinct populations of Leishmania (Viannia) in Colombia. Am J Trop Med Hyg 59: 8694. [Google Scholar]
  19. Berger BA, Cossio A, Saravia NG, Castro MDM, Prada S, Bartlett AH, Pho MT, , 2017. Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis. PLoS Negl Trop Dis 11: e0005459. [Google Scholar]
  20. Cardona-Arias JA, López-Carvajal L, Tamayo Plata MP, Vélez ID, , 2017. Cost-effectiveness analysis of thermotherapy versus pentavalent antimonials for the treatment of cutaneous leishmaniasis. J Evid Based Med 10: 8190. [Google Scholar]
  21. Vanlerberghe V, Diap G, Guerin PJ, Meheus F, Gerstl S, Van der Stuyft P, Boelaert M, , 2007. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis. Trop Med Int Heal 12: 274283. [Google Scholar]
  22. de Oliveira-Neto MP, Mattos MS, Perez MA, Da-Cruz AM, Fernandes O, Moreira J, Gonçalves-Costa SC, Brahin LR, Menezes CR, Pirmez C, , 2000. American tegumentary leishmaniasis (ATL) in Rio de Janeiro State, Brazil: main clinical and epidemiologic characteristics. Int J Dermatol 39: 506514. [Google Scholar]
  23. Machado-Coelho GLL, Caiaffa WT, Genaro O, Magalhães PA, Mayrink W, , 2005. Risk factors for mucosal manifestation of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 99: 5561. [Google Scholar]
  24. Martínez-Valencia AJ, Daza-Rivera CF, Rosales-Chilama M, Cossio A, Casadiego Rincón EJ, Desai MM, Saravia NG, Gómez MA, , 2017. Clinical and parasitological factors in parasite persistence after treatment and clinical cure of cutaneous leishmaniasis. PLoS Negl Trop Dis 11: e0005713. [Google Scholar]
  25. Mendonça MG, de Brito MEF, Rodrigues EHG, Bandeira V, Jardim ML, Abath FGC, , 2004. Persistence of Leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure? J Infect Dis 189: 10181023. [Google Scholar]
  26. Netto EM, Marsden PD, Llanos-Cuentas EA, Costa JML, Cuba CC, Barreto AC, Badaró R, Johnson WD, Jones TC, , 1990. Long-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime®. Trans R Soc Trop Med Hyg 84: 367370. [Google Scholar]
  27. Soto J, 2013. Intralesional antimony for single lesions of Bolivian cutaneous leishmaniasis. Clin Infect Dis 56: 12551260. [Google Scholar]
  28. López L, Robayo M, Vargas M, Vélez ID, , 2012. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis. Trials 13: 58. [Google Scholar]
  29. López L, Cruz C, Godoy G, Robledo SM, Vélez ID, , 2013. Termoterapia efectiva y más segura que la miltefosina en el tratamiento de la leishmaniasis cutánea en Colombia. Rev Inst Med Trop Sao Paulo 55: 197204. [Google Scholar]
  30. Lobo IMF, Soares MBP, Correia TM, de Freitas LAR, Oliveira MI, Nakatani M, Netto E, Badaro R, David JR, , 2006. Heat therapy for cutaneous leishmaniasis elicits a systemic cytokine response similar to that of antimonial (glucantime) therapy. Trans R Soc Trop Med Hyg 100: 642649. [Google Scholar]
  31. Olliaro P, Vaillant M, Arana B, Grogl M, Modabber F, Magill A, Lapujade O, Buffet P, Alvar J, , 2013. Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. PLoS Negl Trop Dis 7: e2130. [Google Scholar]
  32. Jirmanus L, Glesby MJ, Guimarães LH, Lago E, Rosa ME, Machado PR, Carvalho EM, , 2012. Epidemiological and clinical changes in American tegumentary leishmaniasis in an area of Leishmania (Viannia) braziliensis transmission over a 20-year period. Am J Trop Med Hyg 86: 426433. [Google Scholar]
  33. PAHO/WHO, 2018. Leishmaniasis. Epidemiological Report of the Americas. Washington, DC: PAHO. Available at: http://iris.paho.org/xmlui/handle/123456789/34856. Accessed April 10, 2018. [Google Scholar]
  34. Alvar J, Yactayo S, Bern C, , 2006. Leishmaniasis and poverty. Trends Parasitol 22: 552557. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-0643
Loading
/content/journals/10.4269/ajtmh.18-0643
Loading

Data & Media loading...

  • Received : 04 Aug 2018
  • Accepted : 31 Oct 2018
  • Published online : 07 Jan 2019

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error